Kalehua Capital Management
Latest statistics and disclosures from Kalehua Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BOXX, MANE, MANE, XFOR, XFOR, and represent 30.97% of Kalehua Capital Management's stock portfolio.
- Added to shares of these 10 stocks: KPTI (+$6.7M), IFRX (+$6.5M), CYCN (+$5.6M), KRRO, ANL, NVCT, MIST, ATYR, BOXX, TCRX.
- Started 8 new stock positions in TCRX, NVCT, ANL, ATYR, IFRX, KPTI, MIST, CYCN.
- Reduced shares in these 9 stocks: QURE (-$9.8M), RLAY (-$9.0M), ORKA (-$5.8M), PEPG, TNYA, KLRS, TIL, DMAC, LOOP.
- Sold out of its positions in DMAC, KLRS, LOOP, ORKA, PEPG, RLAY, TNYA.
- Kalehua Capital Management was a net buyer of stock by $1.5M.
- Kalehua Capital Management has $314M in assets under management (AUM), dropping by 121.80%.
- Central Index Key (CIK): 0002106181
Tip: Access up to 7 years of quarterly data
Positions held by Kalehua Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Kalehua Capital Management
Kalehua Capital Management holds 49 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ea Series Trust Alpha Arch 1-3 (BOXX) | 8.4 | $27M | +3% | 226k | 117.09 |
|
| Veradermics Common Stock (MANE) | 5.7 | $18M | 146k | 122.94 |
|
|
| Veradermics Coomon Stock (MANE) | 5.7 | $18M | 146k | 122.94 |
|
|
| X4 Pharmaceuticals Com New (XFOR) | 5.5 | $17M | 3.7M | 4.67 |
|
|
| X4 Pharmaceuticals Com New (XFOR) | 5.5 | $17M | 3.7M | 4.67 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 3.7 | $12M | 820k | 14.15 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 3.7 | $12M | 820k | 14.15 |
|
|
| Surrozen Com New (SRZN) | 3.2 | $10M | 385k | 25.95 |
|
|
| Surrozen Com New (SRZN) | 3.2 | $10M | 385k | 25.95 |
|
|
| Aclaris Therapeutics (ACRS) | 3.1 | $9.7M | 1.8M | 5.29 |
|
|
| Aclaris Therapeutics (ACRS) | 3.1 | $9.7M | 1.8M | 5.29 |
|
|
| Sionna Therapeutics (SION) | 2.8 | $8.7M | 197k | 43.99 |
|
|
| Sionna Therapeutics (SION) | 2.8 | $8.7M | 197k | 43.99 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 2.5 | $7.8M | 3.8M | 2.03 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 2.5 | $7.8M | 3.8M | 2.03 |
|
|
| Pharvaris N V (PHVS) | 2.2 | $6.9M | 199k | 34.58 |
|
|
| Pharvaris N V (PHVS) | 2.2 | $6.9M | 199k | 34.58 |
|
|
| Karyopharm Therapeutics Com New (KPTI) | 2.1 | $6.7M | NEW | 686k | 9.77 |
|
| Karyopharm Therapeutics Com New (KPTI) | 2.1 | $6.7M | NEW | 686k | 9.77 |
|
| Septerna (SEPN) | 2.1 | $6.5M | 195k | 33.49 |
|
|
| Septerna (SEPN) | 2.1 | $6.5M | 195k | 33.49 |
|
|
| Inflarx Nv (IFRX) | 2.1 | $6.5M | NEW | 2.9M | 2.24 |
|
| Inflarx Nv (IFRX) | 2.1 | $6.5M | NEW | 2.9M | 2.24 |
|
| Cyclerion Therapeutics (CYCN) | 1.8 | $5.6M | NEW | 1.7M | 3.39 |
|
| Cyclerion Therapeutics (CYCN) | 1.8 | $5.6M | NEW | 1.7M | 3.39 |
|
| Korro Bio (KRRO) | 1.7 | $5.3M | +270% | 405k | 13.18 |
|
| Uniqure Nv SHS (QURE) | 1.2 | $3.7M | -72% | 79k | 46.06 |
|
| Uniqure Nv SHS (QURE) | 1.2 | $3.7M | -72% | 79k | 46.06 |
|
| Athira Pharma (LONA) | 1.2 | $3.6M | 394k | 9.19 |
|
|
| Athira Pharma (LONA) | 1.2 | $3.6M | 394k | 9.19 |
|
|
| Damora Therapeutics Com New (DMRA) | 1.2 | $3.6M | 139k | 26.01 |
|
|
| Damora Therapeutics Com New (DMRA) | 1.2 | $3.6M | 139k | 26.01 |
|
|
| MoonLake Immunotherapeutics Class A Ord (MLTX) | 1.1 | $3.4M | 176k | 19.47 |
|
|
| MoonLake Immunotherapeutics Class A Ord (MLTX) | 1.1 | $3.4M | 176k | 19.47 |
|
|
| Adlai Nortye Sponsored Ads (ANL) | 0.8 | $2.6M | NEW | 226k | 11.50 |
|
| Tyra Biosciences (TYRA) | 0.8 | $2.4M | 75k | 31.94 |
|
|
| Tyra Biosciences (TYRA) | 0.8 | $2.4M | 75k | 31.94 |
|
|
| Nuvectis Pharma (NVCT) | 0.6 | $1.8M | NEW | 100k | 18.39 |
|
| Nuvectis Pharma (NVCT) | 0.6 | $1.8M | NEW | 100k | 18.39 |
|
| Gossamer Bio (GOSS) | 0.6 | $1.8M | +8% | 11M | 0.16 |
|
| Gossamer Bio (GOSS) | 0.6 | $1.8M | +8% | 11M | 0.16 |
|
| Milestone Pharmaceuticals (MIST) | 0.5 | $1.7M | NEW | 1.3M | 1.34 |
|
| Milestone Pharmaceuticals (MIST) | 0.5 | $1.7M | NEW | 1.3M | 1.34 |
|
| Atyr Pharma Com New (ATYR) | 0.3 | $1.1M | NEW | 1.8M | 0.60 |
|
| Atyr Pharma Com New (ATYR) | 0.3 | $1.1M | NEW | 1.8M | 0.60 |
|
| Instil Bio Com New (TIL) | 0.2 | $766k | -45% | 100k | 7.69 |
|
| Instil Bio Com New (TIL) | 0.2 | $766k | -45% | 100k | 7.69 |
|
| Tscan Therapeutics (TCRX) | 0.1 | $446k | NEW | 455k | 0.98 |
|
| Tscan Therapeutics (TCRX) | 0.1 | $446k | NEW | 455k | 0.98 |
|
Past Filings by Kalehua Capital Management
SEC 13F filings are viewable for Kalehua Capital Management going back to 2026
- Kalehua Capital Management 2026 Q2 amended filed Aug. 19, 2026
- Kalehua Capital Management 2026 Q2 filed Aug. 14, 2026
- Kalehua Capital Management 2026 Q1 amended filed May 15, 2026